56961-99-0

Basic information

• Product Name: 2-chlorophenanthrene-9,10-dione
• Synonyms: 2-chlorophenanthrene-9,10-dione;3-chloro-9,10-Phenanthrenedione
• CAS NO: 56961-99-0
• Molecular Formula: C₁₄H₇ClO₂
• Molecular Weight: 242.65718
• Mol File: 56961-99-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-chlorophenanthrene-9,10-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chlorophenanthrene-9,10-dione(56961-99-0)
• EPA Substance Registry System: 2-chlorophenanthrene-9,10-dione(56961-99-0)

Safety Data

• Hazardous Substances Data: 56961-99-0(Hazardous Substances Data)

Upstream product

• 715-51-5 3-chlorophenanthrene 
• 56988-42-2 6-Chlorophenanthrene-9-carboxylic acid 
• 7473-66-7 3,9-Dichlorophenanthrene 
• 171417-44-0 3,10-dichloro-phenanthrene 
• 930796-35-3 1-(5-chloro-[1,1'-biphenyl]-2-yl)ethanone 
• 64-19-7 acetic acid 
• 63503-60-6 3-chlorophenylboronic acid 
• 1892-54-2 3-aminophenanthrene 
• 2039-76-1 1-(phenanthren-3-yl)ethanone 
• 5968-50-3 1-(phenanthren-3-yl)ethanone oxime 

Downstream Products

• 329200-94-4 2,7-dichloro-4-phenyl-1-oxa-2λ⁵-phosphatriphenylene 2-oxide 
• 892550-43-5 6-chloro-2-(2,6-dibromophenyl)-1H-phenanthro[9,10-d]imidazole 

Relevant articles and documents

Copper(0)/Selectfluor System-Promoted Oxidative Carbon-Carbon Bond Cleavage/Annulation of o-Aryl Chalcones: An Unexpected Synthesis of 9,10-Phenanthraquinone Derivatives

A general and efficient protocol for the synthesis of 9,10-phenanthraquinone derivatives has been successfully developed involving a copper(0)/Selectfluor system-promoted oxidative carbon-carbon bond cleavage/annulation of o-aryl chalcones. A variety of substituted 9,10-phenanthraquinones were synthesized in moderate to good yields under mild reaction conditions.

Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors

Phenanthrene imidazole 3 (MF63) has been identified as a novel potent, selective, and orally active mPGES-1 inhibitor. This new series was developed by lead optimization of a hit from an internal HTS campaign. Compound 3 is significantly more potent than the previously reported indole carboxylic acid 1 with an A549 whole cell IC50 of 0.42 μM (50% FBS) and a human whole blood IC50 of 1.3 μM. It exhibited a significant analgesic effect in a guinea pig hyperalgesia model when orally dosed at 30 and 100 mg/kg.

2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS

The invention encompasses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed

2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO [9,10-D] IMIDAZOLES

The invention encompasses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

METHODS FOR TREATING OR PREVENTING NEOPLASIAS

The present invention is directed to a method for treating or preventing a neoplasia in a human patient in need of such treatment comprising administering to the patient a compound that inhibits microsomal prostaglandin E synthase-1 in an amount that is effective for treating or preventing the neoplasia.

2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS

The invention encompasses novel compounds of Formula I INSERT FORMULA I FROM CLAIM 1 or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.